Drug-maker Suven Life Sciences Ltd has informed that its clinical research division Asian Clinical Trials (ACT) has entered into a strategic alliance with VPSCRO, a CRO based in Beijing, China to conduct clinical trial services in India, as well as in China.

This strategic alliance between ACT and VPSCRO will allow the company to offer compressive range of clinical services to global sponsors with the state of the art infrastructure, network of trained investigators in India and China by leveraging their expertise to the conduct quality clinical research.

Recently, Suven Life Sciences secured patent rights in Mexico and Korea for two of its new chemical entities for the treatment of disorders associated with neuro-degenerative diseases.

At 10:17 am, Suven Life was quoting at Rs 36.65, up Rs 3.10, or 9% on NSE. It has touched an intraday high of Rs 36.70 and an intraday low of Rs 34.

The stock had registered a 52-week high of Rs 64.45 on December 28, 2007 and a 52-week low of Rs 28 on October 19, 2007.